Day One Biopharmaceuticals

Day One Biopharmaceuticals is a growing company focused on innovative drug development for targeted cancer therapies, particularly for pediatric patients. Comprising a dedicated team of oncologists, scientists, and professionals, Day One aims to disrupt traditional drug development processes to deliver effective treatment options at a faster pace. Their lead medicine, OJEMDA™, is aimed at addressing pediatric low-grade glioma and showcases their commitment to advancing oncology innovation through rigorous clinical research and collaboration.